A pivotal year for NAFLD and NASH therapeutics

Nat Rev Endocrinol. 2024 Feb;20(2):75-76. doi: 10.1038/s41574-023-00939-9.
No abstract available

MeSH terms

  • Humans
  • Liver
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Risk Factors